Related Experiment Video

Updated: Jun 24, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

CXCR4-Mediated Codelivery of FLT3 and BCL-2 Inhibitors for Enhanced Targeted Combination Therapy of FLT3-ITD Acute

Jiakun Yang1, Peng Zhang1, Yumin Mao1

  • 1Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, P. R. China.

Biomacromolecules
|June 13, 2024
PubMed

Insights

Targeted delivery of venetoclax and sorafenib using T22 peptide-tagged micelles synergistically treats Acute Myeloid Leukemia (AML). This combination therapy improves efficacy and reduces toxicity in FLT3-ITD AML models.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) presents a significant therapeutic challenge with limited monotherapy success.
  • Current combination therapies for AML often suffer from poor bioavailability, toxicity, and drug resistance.

Purpose of the Study:

  • To investigate the efficacy of CXCR4-mediated codelivery of venetoclax (BCL-2 inhibitor) and sorafenib (FLT3 inhibitor) using T22 peptide-tagged polymeric micelles for FLT3-ITD AML treatment.

Main Methods:

  • Development of T22 peptide-tagged disulfide cross-linked polymeric micelles (TM) for codelivery of venetoclax (VEN) and sorafenib (SOR).
  • Evaluation of TM-VS efficacy in CXCR4-overexpressing MV4-11 AML cells and orthotopic mouse models.
  • Comparison with nontargeted micelles and free drug administration.

Main Results:

  • TM-VS formulation with a 1/4 VEN/SOR ratio and 20% T22 peptide density showed significant inhibition of MV4-11 AML cells.
  • In vivo studies demonstrated that TM-VS (2.5/10 mg/kg) markedly reduced leukemia burden, prolonged survival, and prevented bone loss in mice.
  • TM-VS outperformed nontargeted micelles and oral administration of free VEN/SOR.

Conclusions:

  • CXCR4-mediated codelivery of BCL-2 and FLT3 inhibitors via T22-tagged micelles offers a synergistic and effective therapeutic strategy for FLT3-ITD AML.
  • This targeted nanomedicine approach holds promise for improving clinical outcomes in AML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

73
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K